ArticleJournal of the American Medical Informatics Association : JAMIA2016
Automated eligibility screening and monitoring for genotype-driven precision oncology trials.
Article in Journal of the American Medical Informatics Association : JAMIA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Article
- Article
- Clinical Research Informatics: a Decade-in-Review.Yearbook of medical informatics · 2024Review
- OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis.Database : the journal of biological databases and curation · 2023Article
- Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics.Social science & medicine (1982) · 2023Article
- Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Article
- Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.The oncologist · 2022Article
- MatchMiner: an open-source platform for cancer precision medicine.NPJ precision oncology · 2022Article
- Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.Cancers · 2022Review
- Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.Nature medicine · 2022Article
- Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care.Cancers · 2021Article
- The Future of Clinical Trial Design in Oncology.Cancer discovery · 2021Review
- Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients.JAMIA open · 2020Article
- A Real-Time Automated Patient Screening System for Clinical Trials Eligibility in an Emergency Department: Design and Evaluation.JMIR medical informatics · 2019Article
- Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.JCO precision oncology · 2019Article
- A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials.JAMIA open · 2018Article
- Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.Annual review of medicine · 2018Review
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Nature medicine · 2017Article
- Implementing Genome-Driven Oncology.Cell · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The Information Systems Department at Memorial Sloan Kettering Cancer Center developed the DARWIN Cohort Management System (DCMS). The DCMS identifies and tracks cohorts of patients based on genotypic and clinical data. It assists researchers and treating physicians in enrolling patients to genotype-matched IRB-approved clinical trials. The DCMS sends automated, actionable, and secure email notifications to users with information about eligible or enrolled patients before their upcoming appointments. The system also captures investigators input via annotations on patient eligibility and preferences on future status updates. As of August 2015, the DCMS is tracking 159,893 patients on both clinical operations and research cohorts. 134 research cohorts have been established and track 64,473 patients. 51,192 of these have had one or more genomic tests including MSK-IMPACT, comprising the pool eligible for genotype-matched studies. This paper describes the design and evolution of this Informatics solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.